Prosecution Insights
Last updated: April 19, 2026
Application No. 18/548,366

MONOMERS CONTAINING A 4-THIAZOLIDINONE UNIT AND THEIR POLYAMIDE, POLYESTER AND POLYURETHANE POLYCONDENSATES

Non-Final OA §102§112
Filed
Aug 30, 2023
Examiner
HEASLEY, MEGHAN CHRISTINE
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
COMPAGNIE GÉNÉRALE DES ÉTABLISSEMENTS MICHELIN
OA Round
1 (Non-Final)
76%
Grant Probability
Favorable
1-2
OA Rounds
3y 1m
To Grant
99%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allow Rate
83 granted / 109 resolved
+16.1% vs TC avg
Strong +34% interview lift
Without
With
+33.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
35 currently pending
Career history
144
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
33.3%
-6.7% vs TC avg
§102
18.4%
-21.6% vs TC avg
§112
27.2%
-12.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 109 resolved cases

Office Action

§102 §112
Detailed Action Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-10 are pending. Claims 1 and 3-4 are rejected. Claims 2 and 5-10 are withdrawn. Information Disclosure Statement The Information Disclosure Statement from 8/30/2023 was considered by the Examiner. Priority This is a 35 U.S.C. 371 National Stage Filing of International Application No. PNG media_image1.png 24 209 media_image1.png Greyscale , which claims priority under 35 U.S.C. 119(a-d) to PNG media_image2.png 22 186 media_image2.png Greyscale **. Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d). **Foreign priority date is later than PCT date, therefore the priority date is 2/21/2022. Election/Restriction Applicant's election with traverse of Group I (claims 1-4) and the species of a monomer of formula (I-a): PNG media_image3.png 196 195 media_image3.png Greyscale , in the reply filed on 2/3/2026 is acknowledged. The traversal is on the ground(s) that the instant claims make a contribution over CAS Registry No. 1222910-85-1. This is not found persuasive because newly presented art (see 102 rejection below over CAS Registry No. 857964-20-6) was discovered that the instant claims do not make a contribution over. Additionally, on p. 6 of the 2/3/2026 response, Applicant argues that the monomers of claim 1 have the ability to react by polycondensation reaction to synthesize polyamide, polyester and polyurethane having 4-thiazolidinone moiety as repeating unit. While claim 1 does not have this specific limitation included, the art utilized in the rejection under 35 USC 102 below is embraced by a monomer of instant claim 1 and would inherently have such functionality. The requirement is still deemed proper and is therefore made FINAL. Claims 1 and 3-4 embrace applicant’s elected species and are therefore under examination. Applicant’s elected species is not allowable and has been rejected below under 35 USC 102. Claims 2 and 5-10 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 2/3/2026. Claim Objections Claim 1 is objected to because of the following informalities: Examiner recommends deleting the word “else” on p. 3 line 3. Examiner recommends deleting the phrase “which contains carbon atoms” on p. 3, line 4. Appropriate correction is required. Claim 3 is objected to because of the following informalities: In line 1: “Claim 1” should be changed to “claim 1”. Appropriate correction is required. Claim 4 is objected to because of the following informalities: In line 1: “Claim 1” should be changed to “claim 1”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1 and 3-4 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1, line 1 recites: “A monomer, comprising”, wherein “comprising” various elements and monomers is unclear. “Comprising” is an open-ended transitional phrase and the metes and bounds of “comprising” the list of monomers that follow cannot be fully ascertained. Examiner recommends replacing “comprising” with “consisting of”. Claims 3-4 are additionally rejected for depending from claim 1 and failing to remedy its deficiencies. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1 and 3-4 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry No. 857964-20-6 (which entered the STN database on 8/3/2005). Regarding instant claims 1 and 3-4, CAS Registry No. 857964-20-6 is drawn to the following structure: PNG media_image4.png 166 182 media_image4.png Greyscale , which is embraced by a monomer of instant claim 1, I-a: PNG media_image3.png 196 195 media_image3.png Greyscale , wherein Y= hydroxyl; Q = alkyl (methyl); R2 = H. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MEGHAN C HEASLEY whose telephone number is (571)270-0785. The examiner can normally be reached Monday - Friday 8:30-4:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy Clark can be reached at 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MEGHAN C HEASLEY/Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Aug 30, 2023
Application Filed
Mar 09, 2026
Non-Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600716
COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12600715
SOLUBLE GUANYLATE CYCLATE ACTIVATORS FOR TREATING SYSTEMIC SCLEROSIS
2y 5m to grant Granted Apr 14, 2026
Patent 12599560
LIPIDS AND LIPID NANOPARTICLE FORMULATIONS
2y 5m to grant Granted Apr 14, 2026
Patent 12582637
NOVEL TOPICAL FORMULATION FOR INTRADERMAL APPLICATION AND USES THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12577213
DEUTERATED 1,4-BENZODIAZEPINE-2,5-DIONE COMPOUND AND USE THEREOF
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
76%
Grant Probability
99%
With Interview (+33.6%)
3y 1m
Median Time to Grant
Low
PTA Risk
Based on 109 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month